Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Still a Buy?

Oculis Holding AG (NASDAQ:OCS) shares saw an uptick in trading volume on Friday . 14,134 shares were traded during trading, a decline of 61% from the previous session’s volume of 36,600 shares.The stock last traded at $17.52 and had previously closed at $16.58.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Oculis in a report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $29.20.

Oculis Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The company’s fifty day moving average price is $15.72 and its 200 day moving average price is $13.19. The firm has a market capitalization of $692.15 million, a price-to-earnings ratio of -8.85 and a beta of -0.34.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.